Observational studyHuman vaccines & immunotherapeutics2024
High burden of human papillomavirus infection among men in Guangzhou, South China: Implications for HPV vaccination strategies.
Observational study in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Age-specific prevalence of multiple human papillomavirus infections in a clinical cohort of men: a cross-sectional study in Shenzhen, China.Emerging microbes & infections · 2026Article
- Epidemiologic burden, clinical attribution, and implications for immunization strategies of HPV infection among males in Sichuan, China: a large-sample cross-sectional study.Virology journal · 2026Article
- HPV vaccination willingness among 3,081 secondary school parents in China's capital.Human vaccines & immunotherapeutics · 2025Article
- Investigating the correlation between oncogenic HPV, sexually transmitted disease, and vaginal microbiota in patients with normal Pap smear.Iranian journal of microbiology · 2025Article
- Prevalence and Genotype Distribution of Human Papillomavirus in 23,495 Cases in Guangzhou City, Guangdong Province, China.Current microbiology · 2025Article
- Trends in the molecular epidemiology of human papillomavirus in males from the plateau region of Southwest China: an 11-year retrospective analysis (2014-2024).Virology journal · 2025Article
- Prevalence and Genotype Distribution of Human Papillomavirus Among Males in Shantou, China (2019-2023).Health science reports · 2025Article
- Detection of Human Papillomavirus in Urogenital Swabs from Male Patients in Northern Serbia.Pathogens (Basel, Switzerland) · 2025Article
- Retrospective analysis of the impact of human papillomavirus infection in the male genital tract on sperm: from a single center.Frontiers in cellular and infection microbiology · 2025Article
- The role of personal health beliefs and altruistic beliefs in young Chinese adult men's acceptance of the human papillomavirus vaccine.Scientific reports · 2024Article
- Knowledge, Attitudes, and Educational Gaps About Vaccination in Chinese Medical Students and Residents: A Pilot Study from a Single Tertiary Referral Center.Infection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiological and clinical aspects of Human Papillomavirus (HPV) infection in women have been extensively studied. However, there is a lack of information regarding HPV characteristics in males. In this study, we conducted a retrospective and observational study of 3737 consecutive male individuals attending outpatient clinics of Guangdong Women and Children Hospital from 2012 to 2023 in Guangzhou, South China, to determine the age- and genotype-specific prevalence of HPV in men. The results showed the overall prevalence of HPV among men was 42.15% (1575/3737), with variations ranging from 29.55% to 81.31% across distinct diagnostic populations. Low-risk HPV6 (15.47%), HPV11 (8.94%), and high-risk HPV52 (5.51%) were the most common types. The annual HPV prevalence decreased significantly (Z = -3.882,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.